Exhibits chromatin binding activity and transcription factor binding activity. Involved in several processes, including cellular response to cAMP; nervous system development; and response to fungicide. Localizes to nuclear chromatin. Biomarker of breast cancer; diabetic retinopathy; schizophrenia; and transient cerebral ischemia. Orthologous to human KDM1A (lysine demethylase 1A); PARTICIPATES IN histone modification pathway; Notch signaling pathway; INTERACTS WITH aldehydo-D-glucose; bisphenol A; D-glucose.
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KDM1A mRNA, Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to KDM1A promoter]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of KDM1A mRNA
[Valproic Acid co-treated with Arsenic Trioxide] results in increased expression of KDM1A mRNA, [Valproic Acid co-treated with Arsenic Trioxide] results in increased expression of KDM1A protein
[2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine co-treated with 4-biphenylamine co-treated with Benzo(a)pyrene] affects the localization of KDM1A protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of KDM1A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of KDM1A mRNA
[Valproic Acid co-treated with Arsenic Trioxide] results in increased expression of KDM1A mRNA, [Valproic Acid co-treated with Arsenic Trioxide] results in increased expression of KDM1A protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of KDM1A mRNA
[Valproic Acid co-treated with arsenic trioxide] results in increased expression of KDM1A mRNA, [Valproic Acid co-treated with arsenic trioxide] results in increased expression of KDM1A protein
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
